Table 1 Baseline characteristics of study participants involved in the randomized controlled trial.

From: Effect of Lactobacillus casei on lipid metabolism and intestinal microflora in patients with alcoholic liver injury

  PC (n = 46) LP (n = 58) HP (n = 54)
Age, years 52.60 ± 5.67 51.10 ± 3.90 49.6 ± 4.17
Height, cm 166.50 ± 8.02 162.05 ± 4.47 164.10 ± 10.17
Weight, kg 69.6 ± 8.30 69.87 ± 9.08 72.15 ± 10.81
BMI, kg/m2 25.06 ± 1.93 26.63 ± 3.35 26.76 ± 2.71
ALT, U/l 84.41 ± 23.26 81.11 ± 34.66 82.37 ± 32.36
AST, U/l 73.77 ± 44.77 82.88 ± 42.84 78.12 ± 39.56
GGT, U/l 181.46 ± 77.40 164.69 ± 87.40 158.12 ± 82.21
TBIL, μmol/L 26.52 ± 6.73 25.05 ± 9.38 24.65 ± 0.38
Endotoxin, EU/ml 0.35 ± 0.04 0.24 ± 0.03 0.22 ± 0.02
TG, mmol/l 2.27 ± 0.82 1.97 ± 0.66 2.01 ± 0.59
TC, mmol/l 5.98 ± 0.87 5.96 ± 1.05 6.12 ± 1.06
LDLC, mmol/l 5.05 ± 0.85 4.07 ± 0.83 3.95 ± 0.81
HDLC, mmol/l 1.33 ± 0.34 1.28 ± 0.26 1.30 ± 0.31
IL-1β, pg/ml 49.77 ± 3.56 48.84 ± 3.65 52.64 ± 4.55
TNF-α, pg/ml 118.96 ± 13.16 107.03 ± 11.52 116.54 ± 14.87
IL-6, pg/ml 209.05 ± 31.64 210.23 ± 27.31 212.89 ± 24.26
IL-10, pg/ml 76.55 ± 13.89 69.64 ± 14.77 69.14 ± 14.84
Escherichia coli, copies/g 7.88 ± 0.57 8.22 ± 0.89 7.51 ± 1.05
Enterococcus facalis, copies/g 5.09 ± 1.11 4.96 ± 1.25 5.28 ± 1.34
Bacteroides fragilis, copies/g 7.43 ± 1.22 8.27 ± 1.82 8.45 ± 1.27
Bifidobacterium longum, copies/g 5.39 ± 0.38 5.23 ± 0.18 5.33 ± 0.37
Lactobacillus acidophilus, copies/g 5.05 ± 0.93 4.27 ± 1.02 5.12 ± 0.74
Clostridium leptum, copies/g 8.28 ± 1.40 7.88 ± 1.81 7.40 ± 1.51
  1. Values are presented as mean ± SD. One-way ANOVA (for continuous variables) or chi-square test (for categorical variables) was performed to test the group difference at baseline.
  2. ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyltransferase, TBIL total bilirubin, TG triglyceride, TC total cholesterol, HDLC: high density lipoprotein cholesterol, LDLC low density lipoprotein cholesterol, IL-1β interleukin-1β, IL-6 interleukin-6, TNF-α tumor necrosis factor-α, IL-10 interleukin-10, PC Positive control group, LP Low dose intervention group, HP High dose intervention group.